PDCD1 and Hepatic fibrosis: In a recent study, administration of anti-PD-1 immunotherapy to CD-HFD-fed mice increased the number of PD−1+ CD8 but not PD-1+ CD4 T cells, aggravated liver damage, and paradoxically augmented the incidence of liver cancer, independently of the degree of liver fibrosis (48).